JP2008540364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540364A5 JP2008540364A5 JP2008509382A JP2008509382A JP2008540364A5 JP 2008540364 A5 JP2008540364 A5 JP 2008540364A5 JP 2008509382 A JP2008509382 A JP 2008509382A JP 2008509382 A JP2008509382 A JP 2008509382A JP 2008540364 A5 JP2008540364 A5 JP 2008540364A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- mol
- body weight
- treatment
- cationic liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930012538 Paclitaxel Natural products 0.000 claims description 17
- 229960001592 paclitaxel Drugs 0.000 claims description 17
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 125000002091 cationic group Chemical group 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000010109 chemoembolization Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- -1 cationic lipid Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 18
- 229960005277 gemcitabine Drugs 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000009097 single-agent therapy Methods 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 238000001802 infusion Methods 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 238000011255 standard chemotherapy Methods 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05009847 | 2005-05-04 | ||
| EP05009847.4 | 2005-05-04 | ||
| PCT/EP2006/004185 WO2006117220A2 (en) | 2005-05-04 | 2006-05-04 | Method of administering a cationic liposomal preparation comprising paclitaxel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540364A JP2008540364A (ja) | 2008-11-20 |
| JP2008540364A5 true JP2008540364A5 (https=) | 2015-02-12 |
| JP5700909B2 JP5700909B2 (ja) | 2015-04-15 |
Family
ID=36809032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509382A Expired - Fee Related JP5700909B2 (ja) | 2005-05-04 | 2006-05-04 | パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9233094B2 (https=) |
| EP (1) | EP1896007B1 (https=) |
| JP (1) | JP5700909B2 (https=) |
| AU (1) | AU2006243337B2 (https=) |
| CA (1) | CA2601067A1 (https=) |
| WO (1) | WO2006117220A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004249172A1 (en) | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
| US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| EP1896007B1 (en) | 2005-05-04 | 2014-03-19 | Medigene AG | Method of administering a cationic liposomal preparation comprising paclitexel |
| BRPI0709075A2 (pt) * | 2006-03-20 | 2011-10-11 | Medigene Ag | tratamento de cáncer de mama triplo receptor negativo |
| RU2496482C2 (ru) | 2008-03-05 | 2013-10-27 | Бакстер Интернэшнл Инк. | Композиции и способы для доставки лекарственных средств |
| KR101975843B1 (ko) * | 2008-05-23 | 2019-05-09 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 리포좀 나노입자에 사용하기 위한 변형된 약물 |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| EP3141245A1 (en) | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
| TWI852903B (zh) * | 2017-01-05 | 2024-08-21 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| JP7055820B2 (ja) * | 2017-05-26 | 2022-04-18 | ブルーイン バイオサイエンシズ，インコーポレイテッド | 化学塞栓療法剤 |
| WO2024160190A1 (zh) * | 2023-01-31 | 2024-08-08 | 石药集团中奇制药技术（石家庄）有限公司 | 紫杉醇阳离子脂质体治疗肿瘤的用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254135B (it) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica. |
| ATE194767T1 (de) | 1992-03-23 | 2000-08-15 | Univ Georgetown | In liposomen verkapseltes taxol und verwendungsverfahren |
| CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| DE4430593C2 (de) | 1994-08-20 | 1999-01-14 | Max Delbrueck Centrum | Verfahren zur Herstellung von Liposomal verkapseltem Taxol |
| US5834012A (en) | 1995-05-03 | 1998-11-10 | Roman Perez-Soler | Lipid complexed topoisomerase I inhibitors |
| US20030087954A1 (en) * | 1997-01-07 | 2003-05-08 | Sonus Pharmaceuticals, Inc. | Method of treating bladder carcinoma using a Taxane/Tocopherol formulation |
| US5837283A (en) | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| US6214821B1 (en) | 1998-03-05 | 2001-04-10 | Washington State University Research Foundation | Methods and composition for the inhibition of cancer cells |
| US7314637B1 (en) | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| US6146659A (en) | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| KR100591767B1 (ko) * | 1999-09-09 | 2006-06-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀 |
| AU2001253334A1 (en) * | 2000-04-10 | 2001-10-23 | Teva Pharmaceutical Industries Ltd. | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| PL366025A1 (pl) | 2000-05-03 | 2005-01-24 | Munich Biotech Ag | Kationowe środki diagnostyczne, obrazujące i terapeutyczne, zasocjowane z uaktywnionymi miejscami wnaczyniach |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| UY27185A1 (es) * | 2001-02-28 | 2002-09-30 | Bristol Myers Squibb Co | Dosificación metronómica de taxanos |
| US20030008014A1 (en) * | 2001-06-20 | 2003-01-09 | Shelness Gregory S. | Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells |
| CN1555253A (zh) * | 2001-09-13 | 2004-12-15 | ������ѧ�����о�Ժ | 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法 |
| ES2292848T3 (es) | 2001-10-12 | 2008-03-16 | Elan Pharma International Limited | Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada. |
| US6627614B1 (en) | 2002-06-05 | 2003-09-30 | Super Gen, Inc. | Sequential therapy comprising a 20(S)-camptothecin and an anthracycline |
| EP1553924B1 (en) | 2002-06-26 | 2010-12-08 | MediGene AG | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| EP1530465B2 (en) | 2002-06-26 | 2015-12-16 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| US20040076582A1 (en) * | 2002-08-30 | 2004-04-22 | Dimatteo Kristian | Agent delivery particle |
| US20080039533A1 (en) | 2003-07-31 | 2008-02-14 | 3M Innovative Properties Company | Bioactive Compositions Comprising Triazines |
| WO2005039533A1 (en) | 2003-10-15 | 2005-05-06 | Medigene Ag | Method of administering cationic liposomes comprising an active drug |
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US7563570B2 (en) * | 2004-10-29 | 2009-07-21 | Pangaea Biotech | Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression |
| EP1896007B1 (en) | 2005-05-04 | 2014-03-19 | Medigene AG | Method of administering a cationic liposomal preparation comprising paclitexel |
| BRPI0709075A2 (pt) | 2006-03-20 | 2011-10-11 | Medigene Ag | tratamento de cáncer de mama triplo receptor negativo |
| EP2073823A1 (en) | 2006-10-13 | 2009-07-01 | Medigene AG | Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer |
-
2006
- 2006-05-04 EP EP06742802.9A patent/EP1896007B1/en not_active Expired - Lifetime
- 2006-05-04 AU AU2006243337A patent/AU2006243337B2/en not_active Ceased
- 2006-05-04 CA CA002601067A patent/CA2601067A1/en not_active Abandoned
- 2006-05-04 US US11/919,700 patent/US9233094B2/en not_active Expired - Fee Related
- 2006-05-04 WO PCT/EP2006/004185 patent/WO2006117220A2/en not_active Ceased
- 2006-05-04 JP JP2008509382A patent/JP5700909B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-04 US US14/959,497 patent/US9827196B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2409755T3 (es) | Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado | |
| JP2008540364A5 (https=) | ||
| JP2012067116A5 (https=) | ||
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| JP2011511072A5 (https=) | ||
| Stuart | First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer | |
| CN104955452B (zh) | 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途 | |
| CN101001623A (zh) | 抗癌效果增强剂 | |
| JP2002544231A5 (https=) | ||
| JP2018528185A5 (https=) | ||
| EP2802352A1 (en) | Combination therapy for the treatment of cancer | |
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| WO2015172712A1 (zh) | 维生素c与抗肿瘤药物协同作用的注射用药物组合物 | |
| JP2008517991A5 (https=) | ||
| KR101226631B1 (ko) | 항암 치료 방법 | |
| TW200808327A (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma | |
| Burstein et al. | Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules | |
| KR101560339B1 (ko) | 의약 조성물 또는 조합제 | |
| Frampton et al. | Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma | |
| Kosmas et al. | Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours | |
| JP7752698B2 (ja) | ミトキサントロン塩酸塩リポソームの応用 | |
| Trafalis et al. | Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma | |
| Rowinsky et al. | Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer | |
| EP3010508A1 (en) | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy | |
| JP2006524678A (ja) | 耐性乳癌の治療のためのイリノテカンの使用 |